Dr. Gillis joined ARCH as a Venture Partner in 2005 and became a Managing Director in 2006. He is focused on the evaluation of new life science technologies and on the development and growth of ARCH’s biotechnology portfolio companies. He is a director of Homology Medicines and Carrick Therapeutics. He serves as director and Chairman of Codiak Biosciences, Faraday Pharmaceuticals, eGenesis, HiberCell, Skylark Bio, Walden Biosciences, OncoResponse, Mozart Therapeutics, Bitterroot Bio, and VBI Vaccines. Dr. Gillis also serves as a director of Takeda Pharmaceuticals.
Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College.